Cromlish W A, Kennedy B P
Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Merck Frosst Canada Inc., Point Claire-Dorval, Québec, Canada.
Biochem Pharmacol. 1996 Dec 13;52(11):1777-85. doi: 10.1016/s0006-2952(96)00599-0.
We have utilized the baculovirus expression system to develop an in vitro intact cell assay for screening nonsteroidal anti-inflammatory drug (NSAID) inhibition of the two isozymes of human cyclooxygenase (prostaglandin endoperoxidase synthase, EC 1.14.99.1). Infected Spodoptera frugiperda (sf9) cells expressing either human cyclooxygenase-1 (hCOX-1) or human cyclooxygenase-2 (hCOX-2) were harvested 24 hr postinfection, a time point where all cells are viable and hCOX-1 or hCOX-2 are correctly processed. Cells were distributed to a 96-well plate, preincubated with various NSAIDs, and challenged with 10 microM arachidonic acid; then cyclooxygenase activity was assessed indirectly by prostaglandin E2-specific radioimmunoassay. The rank order of potency of NSAID-mediated inhibitions of hCOX-1 and hCOX-2 paralleled those that have been observed in other cell systems. This sf9 cell-based assay can be utilized for the identification of potent and selective inhibitors of hCOX-1 and/or hCOX-2. Compounds that preferentially inhibit hCOX-2 may provide novel NSAIDs that reduce inflammation while sparing the stomach and kidneys of toxic side-effects seen with current nonselective NSAIDs.
我们利用杆状病毒表达系统开发了一种体外完整细胞检测方法,用于筛选非甾体抗炎药(NSAID)对人环氧化酶(前列腺素内过氧化物合酶,EC 1.14.99.1)两种同工酶的抑制作用。感染后24小时收获表达人环氧化酶-1(hCOX-1)或人环氧化酶-2(hCOX-2)的草地贪夜蛾(sf9)细胞,这是一个所有细胞均存活且hCOX-1或hCOX-2得到正确加工的时间点。将细胞接种到96孔板中,先用各种NSAID进行预孵育,然后用10微摩尔花生四烯酸进行刺激;然后通过前列腺素E2特异性放射免疫测定间接评估环氧化酶活性。NSAID介导的对hCOX-1和hCOX-2抑制作用的效力排序与在其他细胞系统中观察到的情况相似。这种基于sf9细胞的检测方法可用于鉴定hCOX-1和/或hCOX-2的强效和选择性抑制剂。优先抑制hCOX-2的化合物可能会提供新型NSAID,既能减轻炎症,又能避免当前非选择性NSAID所见的胃和肾毒性副作用。